Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

KARYOPHARM THERAPEUTICS INC.

(KPTI)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

KARYOPHARM THERAPEUTICS INC. : Regulation FD Disclosure (form 8-K)

12/08/2021 | 07:03am EST

Item 7.01 Regulation FD Disclosure.

As previously announced, Karyopharm Therapeutics Inc. (the "Company") will host a virtual Investor Day today, Wednesday, December 8, 2021 from 10:00 a.m. to 12:30 p.m. ET. The slides accompanying the presentations can be viewed by accessing the live video webcast of the event under "Events & Presentations" in the "Investors" section of the Company's website (www.karyopharm.com) beginning at 10:00 a.m. ET today. A copy of the presentation slides will be available under "Events & Presentations" in the "Investors" section of the Company's website after the event. The information contained in, or that can be accessed through the Company's website, is not a part of this filing.

The information in this Item 7.01 shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses

All news about KARYOPHARM THERAPEUTICS INC.
01/24Karyopharm to Present at B. Riley Securities Oncology Investor Conference
AQ
01/24Karyopharm Therapeutics Gets Orphan Drug Designation for Myelodysplastic Syndromes Trea..
MT
01/24Karyopharm Gets FDA Orphan Designation for Eltanexor in Myelodysplastic Syndromes
DJ
01/24Karyopharm Receives Orphan Drug Designation from FDA for Eltanexor for the Treatment of..
PR
01/21Karyopharm to Present at B. Riley Securities Oncology Investor Conference
PR
01/20KARYOPHARM THERAPEUTICS : Corporate Presentation January 2022
PU
01/11Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2021 Net Produc..
AQ
01/10Wedbush Adjusts Price Target for Karyopharm Therapeutics to $9 From $8, Maintains Neutr..
MT
01/10Karyopharm Provides Preliminary Q4, 2021 Net Product Revenue for Xpovio
MT
01/10KARYOPHARM THERAPEUTICS : Announces Preliminary Unaudited Fourth Quarter and Full Year 202..
PU
More news
Analyst Recommendations on KARYOPHARM THERAPEUTICS INC.
More recommendations
Financials (USD)
Sales 2021 115 M - -
Net income 2021 -191 M - -
Net Debt 2021 56,2 M - -
P/E ratio 2021 -3,09x
Yield 2021 -
Capitalization 591 M 591 M -
EV / Sales 2021 5,64x
EV / Sales 2022 4,20x
Nbr of Employees 432
Free-Float 90,3%
Chart KARYOPHARM THERAPEUTICS INC.
Duration : Period :
Karyopharm Therapeutics Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends KARYOPHARM THERAPEUTICS INC.
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Last Close Price 7,83 $
Average target price 14,00 $
Spread / Average Target 78,9%
EPS Revisions
Managers and Directors
Richard A. Paulson President, CEO & Non-Executive Director
Michael P. Mason Treasurer, Chief Financial & Accounting Officer
Sharon Shacham Co-Founder
Jatin Shah Chief Medical Officer & Executive Vice President
Yosef Landesman Senior VP-Research & Translational Medicine
Sector and Competitors
1st jan.Capi. (M$)
KARYOPHARM THERAPEUTICS INC.21.70%591
GILEAD SCIENCES, INC.-7.35%84 382
REGENERON PHARMACEUTICALS-4.16%63 645
VERTEX PHARMACEUTICALS3.93%58 082
WUXI APPTEC CO., LTD.-11.62%47 040
BIONTECH SE-40.05%37 325